Particularly, CD123 CAR-T cells engineered to secrete IL15 displayed higher anti-AML activity, remained in a less differentiated state, and showed a significant survival advantage in AML xenograft and in autologous patient-derived xenograft models [123]. The gene discussed is IL15; the disease is acute myeloid leukemia.